首款国产Bcl-2抑制剂“首方”快速落地。据亚盛医药消息,7月25日,其Bcl-2抑制剂利生妥(通用名:利沙托克拉)已在北京、天津、广州、上海、苏州、福州等30多个城市、40余家医院,开出第一批首方。此时,距离利生妥获批不到20天。对于患者而言,意味着这一中国原创药物将开始惠及广泛的CLL/SLL患者,填补国内相关领域的临床治疗空白,具有里程碑意义。对于亚盛医药而言,利生妥商业化快速推进,意味着其...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.